• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种使用Cox模型在数据子集上评估治疗-协变量相互作用的图形方法。

A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data.

作者信息

Bonetti M, Gelber R D

机构信息

Department of Biostatistics, Harvard School of Public Health and Dana-Farber Cancer Institute, Boston, MA 02115, USA.

出版信息

Stat Med. 2000 Oct 15;19(19):2595-609. doi: 10.1002/1097-0258(20001015)19:19<2595::aid-sim562>3.0.co;2-m.

DOI:10.1002/1097-0258(20001015)19:19<2595::aid-sim562>3.0.co;2-m
PMID:10986536
Abstract

We introduce the subpopulation treatment effect pattern plot (STEPP) method, designed to facilitate the interpretation of estimates of treatment effect derived from different but potentially overlapping subsets of clinical trial data. In particular, we consider sequences of subpopulations defined with respect to a covariate, and obtain confidence bands for the collection of treatment effects (here obtained from the Cox proportional hazards model) associated with the sequences. The method is aimed at determining whether the magnitude of the treatment effect changes as a function of the values of the covariate. We apply STEPP to a breast cancer clinical trial data set to evaluate the treatment effect as a function of the oestrogen receptor content of the primary tumour.

摘要

我们介绍了亚组治疗效应模式图(STEPP)方法,该方法旨在便于解释从临床试验数据的不同但可能重叠的子集中得出的治疗效应估计值。具体而言,我们考虑根据一个协变量定义的亚组序列,并获得与这些序列相关的治疗效应集合(此处从Cox比例风险模型获得)的置信带。该方法旨在确定治疗效应的大小是否随协变量值的变化而变化。我们将STEPP应用于一个乳腺癌临床试验数据集,以评估作为原发肿瘤雌激素受体含量函数的治疗效应。

相似文献

1
A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data.一种使用Cox模型在数据子集上评估治疗-协变量相互作用的图形方法。
Stat Med. 2000 Oct 15;19(19):2595-609. doi: 10.1002/1097-0258(20001015)19:19<2595::aid-sim562>3.0.co;2-m.
2
Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.使用事件亚组识别临床试验中的治疗效果异质性:STEPP法
Clin Trials. 2016 Apr;13(2):169-79. doi: 10.1177/1740774515609106. Epub 2015 Oct 22.
3
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.皇家马斯登医院他莫昔芬预防乳腺癌随机双盲试验的20年随访
J Natl Cancer Inst. 2007 Feb 21;99(4):283-90. doi: 10.1093/jnci/djk050.
4
Patterns of treatment effects in subsets of patients in clinical trials.临床试验中患者亚组的治疗效果模式。
Biostatistics. 2004 Jul;5(3):465-81. doi: 10.1093/biostatistics/5.3.465.
5
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.根据中心评估的ERBB2状态,来曲唑与他莫昔芬作为绝经后内分泌反应性早期乳腺癌女性辅助治疗的比较:BIG 1-98随机试验的补充结果
Lancet Oncol. 2008 Jan;9(1):23-8. doi: 10.1016/S1470-2045(07)70386-8. Epub 2007 Dec 20.
6
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.淋巴结阴性、雌激素受体阳性乳腺癌的治疗:国家外科辅助乳腺和肠道项目随机临床试验的长期结果
Lancet. 2004;364(9437):858-68. doi: 10.1016/S0140-6736(04)16981-X.
7
Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.特定不良反应事件可预测接受他莫昔芬或芳香化酶抑制剂治疗的患者的生存获益:国际他莫昔芬依西美坦辅助多国试验分析。
J Clin Oncol. 2013 Jun 20;31(18):2257-64. doi: 10.1200/JCO.2012.45.3068. Epub 2013 Apr 22.
8
A parametric model for long-term follow-up data from phase III breast cancer clinical trials.一种用于III期乳腺癌临床试验长期随访数据的参数模型。
Stat Med. 2003 Feb 15;22(3):339-52. doi: 10.1002/sim.1349.
9
Factors influencing loco-regional relapse in older breast cancer patients treated with tumour resection and tamoxifen.影响接受肿瘤切除术和他莫昔芬治疗的老年乳腺癌患者局部区域复发的因素。
Eur J Surg Oncol. 2011 Dec;37(12):1051-8. doi: 10.1016/j.ejso.2011.07.005. Epub 2011 Aug 16.
10
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.他莫昔芬用于早期乳腺癌:随机试验综述。早期乳腺癌试验者协作组
Lancet. 1998 May 16;351(9114):1451-67.

引用本文的文献

1
Role of tumor mutational burden in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis.肿瘤突变负荷在接受免疫检查点抑制剂治疗的尿路上皮癌患者中的作用:一项系统评价和荟萃分析。
Front Immunol. 2025 May 26;16:1592761. doi: 10.3389/fimmu.2025.1592761. eCollection 2025.
2
Tumour Mutational Burden and Immune Checkpoint Inhibitor Response in Non-small Cell Lung Cancer: A Continuous Modelling Approach.非小细胞肺癌中的肿瘤突变负荷与免疫检查点抑制剂反应:一种连续建模方法
Target Oncol. 2025 Mar;20(2):361-369. doi: 10.1007/s11523-024-01124-2. Epub 2025 Jan 7.
3
Assessing heterogeneity in surrogacy using censored data.
使用删失数据评估代孕中的异质性。
Stat Med. 2024 Jul 30;43(17):3184-3209. doi: 10.1002/sim.10122. Epub 2024 May 29.
4
Effectiveness of septoplasty compared to medical management in adults with obstruction associated with a deviated nasal septum: the NAIROS RCT.鼻中隔成形术与药物治疗成人鼻中隔偏曲伴阻塞的疗效比较:NAIROS RCT。
Health Technol Assess. 2024 Mar;28(10):1-213. doi: 10.3310/MVFR4028.
5
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer.曲妥珠单抗治疗早期 HER2 阳性乳腺癌中 HER2 生物标志物水平的预后影响。
Breast Cancer Res. 2024 Feb 7;26(1):24. doi: 10.1186/s13058-024-01779-9.
6
Renal function modifies the association between hemoconcentration and outcomes in hospitalized heart failure patients.肾功能改变了血液浓缩与住院心力衰竭患者结局之间的关联。
Intern Emerg Med. 2024 Mar;19(2):399-411. doi: 10.1007/s11739-023-03488-1. Epub 2024 Jan 17.
7
Effects of remnant cholesterol on the efficacy of genotype-guided dual antiplatelet in loss-of -function carriers with minor stroke or transient ischaemic attack: a post-hoc analysis of the CHANCE-2 trial.残余胆固醇对轻度卒中或短暂性脑缺血发作功能丧失携带者中基因分型指导的双重抗血小板疗效的影响:CHANCE-2试验的事后分析
EClinicalMedicine. 2023 Dec 2;67:102357. doi: 10.1016/j.eclinm.2023.102357. eCollection 2024 Jan.
8
Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced non-small-cell lung cancer.II期JO25567研究的生物标志物分析:比较厄洛替尼联合或不联合贝伐单抗用于一线晚期非小细胞肺癌的疗效
Transl Lung Cancer Res. 2023 Jun 30;12(6):1167-1184. doi: 10.21037/tlcr-22-632. Epub 2023 Jun 13.
9
A scoping review of statistical methods in studies of biomarker-related treatment heterogeneity for breast cancer.生物标志物相关治疗异质性研究中统计方法的范围综述——以乳腺癌为例。
BMC Med Res Methodol. 2023 Jun 29;23(1):154. doi: 10.1186/s12874-023-01982-w.
10
Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek.寻找(生物标志物定义的)从新型疗法中获益的患者亚组:没有时间玩捉迷藏了。
Clin Trials. 2023 Aug;20(4):341-350. doi: 10.1177/17407745231169692. Epub 2023 Apr 24.